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Abstract
Introduction: The aim of this review was to identify and evaluate existing research to determine the clinical
effectiveness and safety of prolotherapy injections for treatment of lower limb tendinopathy and fasciopathy.
Review: Nine databases were searched (Medline, Science Direct, AMED, Australian Medical Index, APAIS-Health,
ATSIhealth, EMBASE, Web of Science, OneSearch) without language, publication or data restrictions for all relevant
articles between January 1960 and September 2014. All prospective randomised and non-randomised trials, cohort
studies, case-series, cross-sectional studies and controlled trials assessing the effectiveness of one or more
prolotherapy injections for tendinopathy or fasciopathy at or below the superior aspect of the tibia/fibula were
included. Methodological quality of studies was determined using a modified evaluation tool developed by the
Cochrane Musculoskeletal Injuries Group. Data analysis was carried out to determine the mean change of outcome
measure scores from baseline to final follow-up for trials with no comparative group, and for randomised controlled
trials, standardised mean differences between intervention groups were calculated. Pooled SMD data were
calculated where possible to determine the statistical heterogeneity and overall effect for short-, intermediate- and
long-term data. Adverse events were also reported.
Two hundred and three studies were identified, eight of which met the inclusion criteria. These were then grouped
according to tendinopathy or fasciopathy being treated with prolotherapy injections: Achilles tendinopathy, plantar
fasciopathy and Osgood-Schlatter disease. The methodological quality of the eight included studies was generally
poor, particularly in regards to allocation concealment, intention to treat analysis and blinding procedures. Results
of the analysis provide limited support for the hypothesis that prolotherapy is effective in both reducing pain and
improving function for lower limb tendinopathy and fasciopathy, with no study reporting a mean negative or non-
significant outcome following prolotherapy injection. The analysis also suggests prolotherapy injections provide
equal or superior short-, intermediate- and long-term results to alternative treatment modalities, including eccentric
loading exercises forAchilles tendinopathy, platelet-rich plasma for plantar fasciopathy and usual care or lignocaine
injections for Osgood-Schlatter disease. No adverse events following prolotherapy injections were reported in any
study in this review.
Conclusions: The conclusions of this review were derived from the best available scientific evidence. It is intended
that the results of this study will assist clinical decision-making by practitioners. The results of this review found
limited evidence that prolotherapy injections are a safe and effective treatment for Achilles tendinopathy, plantar
fasciopathy and Osgood-Schlatter disease, however more robust research using large, methodologically-sound
randomised controlled trials is required to substantiate these findings.
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Introduction
Lower-limb pain has been identified as a risk factor for
locomotor disability, impaired balance, increased risk of
falling and reduced health-related quality of life [1]. Causes
of lower limb pain are varied, including but not limited to,
osteoarthritis, previous trauma, inflammatory and overuse
injuries [1, 2]. Current non-surgical treatments for lower-
limb musculoskeletal pain include activity modification,
physical therapy, therapeutic ultrasound, extracorporeal
shock wave therapy, dry needling, strapping, foot orthoses,
mobilisations, corticosteroid injection, platelet-rich plasma
injection and prolotherapy injection [1, 2].
Prolotherapy, as defined by Webster’s Third New Inter-
national Dictionary, is “the rehabilitation of an incompe-
tent structure, such as a ligament or tendon, by the
induced proliferation of new cells” [3]. It is an increasingly
popular regenerative injection technique for treatment of
a wide range of musculoskeletal pathologies [3]. Most pro-
lotherapy research focuses on its use in sprained and
degenerated ligaments, however it is also reported to be
an effective treatment for concomitant pain and joint dys-
functions caused by laxity of damaged periarticular dense
connective tissues, and can be applied to other damaged
dense connective tissues structures such as tendons and
entheses [4–12]. The most commonly used prolotherapy
substance reported in current literature is dextrose, a
simple aldostic monosaccharide synonymous with glu-
cose that is readily available in Australia and the United
Kingdom in various concentrations [12].
The mechanism of action, safety and efficacy of dex-
trose prolotherapy is well represented in current litera-
ture. It is hypothesised that injection of dextrose causes
local cell necrosis as a direct result of osmotic shock [5].
It is hypothesised that this method of intentional small
scale “therapeutic trauma” at the injection site initiates
the body’s wound healing cascade of inflammation,
granulation tissue formation, and matrix formation and
remodelling [11–13]. As stresses are placed on the new
tissue, the collagen fibres align in the direction of the
stress [11–13]. The effect of dextrose on the biomechan-
ical properties of human tendons and the histological
analysis are as yet unknown [5]. According to deChelli
et al. [14], Rabago et al. [15] and Rabago et al. [16], the
use of prolotherapy injections has been predominantly
guided by anecdotal clinical success. Randomised con-
trolled trials have demonstrated Level I - III evidence (as
per the National Health and Medical Research Council
designations of levels of evidence [17]) for injection of
10 to 25 % dextrose in areas of damaged ligament, tendon,
and cartilage in adults to manage finger osteoarthritis,
knee osteoarthritis, lateral epicondylosis, sacroiliac joint
pain [18–21]. Several case-series reports of participants
with anterior cruciate ligament laxity, coccygodynia,
abdominal tendinosis and chronic back, hip adductor,
ankle, foot and first metatarsophalangeal pain have also
reported in favour of prolotherapy, however the poor
methodological quality of these studies significantly re-
duces the weight of these findings [22–29].
Prolotherapy has been reported with increasing fre-
quency in recent literature for treatment of chronic,
painful lower-limb tendon and fascia overuse conditions
[30–37]. These were formerly associated with the suffix ‘–
itis’ but this has changed to ‘-osis’ or ‘-opathy’ to reflect
existing underlying pathology [2]. Most prominently in
the lower-limb, these include Achilles tendinopathy and
plantar fasciopathy [30–36]. Recent evidence also suggests
that prolotherapy injections may be an effective treatment
for painful traction apophysitis pathologies through treat-
ment of associated tendinopathy; such as patellar tendino-
pathy associated with Osgood-Schlatter disease [37]. In
this situation, it is speculated that prolotherapy may re-
verse the neovascularisation accompanying tendinopathy
and fasciopathy and stimulate the release of multiple
growth factors that aid in tissue repair [37].
In examining the safety of prolotherapy, Dorman con-
ducted a retrospective analysis of 494,845 participants who
all underwent prolotherapy injections for various patholo-
gies [38]. Dorman reported that very few adverse effects
were found following prolotherapy injections and of these,
the majority of serious complications were overwhelmingly
in areas of the body outside the lower limb [38]. These in-
cluded 29 reports of pneumothoraces, 24 reports of allergic
reactions (none classified as serious) and 12 other reports of
hospitalisation [38]. It should be noted that significant recall
bias was present in Dorman’s study as the practitioners sur-
veyed were reporting on complications in their patients en-
tirely from memory [38]. Many of the procedures in
Dorman’s study also used injections of overt sclerosants no
longer used (such as zinc sulphate, which reportedly resulted
in the death of a patient who received a lower-back injection
in 1959), rather than the simple local anaesthetics and dex-
trose that are most commonly used today [38, 39].
Prolotherapy has been suggested to be a safe and effective
treatment for a range of axial and upper limb pathologies.
The proposed benefits of prolotherapy injections in muscu-
loskeletal pathologies are based on the premise that clinical
improvement is derived from inducing inflammation to
stimulate the body’s wound healing cascade, enabling the
repair of damaged tissue and new collagen formation, along
with a reduction in associated neovascularity. The aim of
this study was to review the clinical effectiveness and safety




The question asked in this systematic review is placed
under the category of ‘interventions’— as described by
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the National Health and Medical Research Council
(NHMRC) handbook on conducting systematic reviews
[40]. In preparing this review, the NHMRC criteria for
reviewing ‘interventions’ was used as a guide.
Selection of studies for inclusion
The types of studies considered for this review included
both randomised and non-randomised trials, cohort stud-
ies, case-series, cross-sectional studies and controlled
trials. Exclusion criteria included retrospective studies
without a comparative control group, case reports, sys-
tematic reviews, review articles and general articles. While
the authors would have preferred to include only rando-
mised or quasi-randomised controlled trials in this review
this would have significantly reduced the number of stud-
ies included in the analysis. All participants presenting for
treatment of tendon or fascia pathology at or below the
superior margin of tibia/fibula were included. Studies in-
volving non-human participants (i.e. rats) were excluded.
All age groups and both sexes were included.
For the purpose of this review, all treatments that were
described as ‘prolotherapy’ were considered. Trials
undertaken where no specific treatment was reported
were excluded. The concentrations of dextrose and add-
itional local anaesthetic solutions and concentrations
varied between studies, and are described in detail in the
‘Description of studies’ section. Outcomes sought in-
cluded both objective and subjective outcomes.
Objective data included in the analyses were:
(i) Sonographic measurements (tendon thickness, size
of hypoechoic region and intratendinous tear size).
(ii) Post-intervention adverse events (total number of
complications from each intervention was
analysed).
(iii) Post-intervention return to activity (number of
participants able to return to a particular activity).
Subjective outcome measures included in the analyses
were:
(i) Post-intervention pain levels (the number of
participants remaining in pain, or the pain level
measured on a 0–100 mm visual analogue scale
was used for the purposes of this review).
(ii) Post-intervention satisfaction levels (the number of
participants dissatisfied or the level of
dissatisfaction on a 0–100 mm visual analogue
scale at the end of the trial was used).
(iii) Pathology or location-specific outcome
measures (this includes the Victorian
Institute of Sport Assessment-Achilles (VISA-A),
Foot Function Index (FFI), stiffness and limited
range of motion).
Search methods for identification of studies
This systematic review was reported in accordance with
Cochrane Collaboration and NHMRC guidelines [40, 41].
One reviewer (LS) conducted all screening of identified
studies according to the pre-determined inclusion criteria.
The Cochrane library was searched initially to ensure no
systematic reviews had previously been conducted on
this topic. Nine databases were systematically reviewed
(Medline, Science Direct, AMED, Australian Medical
Index, APAIS-Health, ATSIhealth, EMBASE, Web of
Science, OneSearch) without language, publication or data
restrictions for all relevant articles from January 1960 to
September 2014, with the search keywords and synonyms
of: Prolotherapy AND (tendonosis OR paratendonitis OR
tendonitis OR tenosynovitis OR tendinopathy OR fasciitis
OR fasciopathy OR foot OR ankle OR leg). Titles and
abstracts were screened initially and those found to
be irrelevant were excluded prior to screening full-text
manuscripts.
Citations within obtained articles were hand-searched
and scrutinised to identify additional studies. The rele-
vant databases on the above list were searched for com-
pleted published, unpublished and ongoing unpublished
studies. Conference proceedings were examined using
the Index to Scientific and Technical Conference Pro-
ceedings [42]. Attempts to access the grey literature
were made using the Health Management Information
Consortium database, and System for Information on
Grey Literature. The Australian New Zealand Clinical
Trials Registry, National Institutes of Health Inventory
of Clinical Trials and Studies, as well as the International
Standard Randomised Controlled Trial Number database
to ensure no other trials similarly assessing prolotherapy
were commenced but never published. Attempts to access
articles written in languages other than English were made
using the Virtual Health Library and foreign language arti-
cles with abstracts were assessed. All relevant review arti-
cles and systematic reviews were also analysed to ensure
no other relevant studies were missed.
Quality assessment
An assessment of methodological quality was under-
taken by one assessor (LS) using an evaluation tool devel-
oped by the Cochrane Musculoskeletal Injuries Group,
which was modified for use in this systematic review. The
following aspects of internal and external validity were
considered:
A. Was the assigned treatment adequately concealed
prior to allocation?
2 =method did not allow disclosure of assignment
1 = small but possible chance of disclosure of
assignment or unclear
0 = quasi-randomised or open-list/table
Sanderson and Bryant Journal of Foot and Ankle Research  (2015) 8:57 Page 3 of 15
B. Were the outcomes of participants who withdrew
described and included in the analysis (intention to
treat)?
2 = withdrawals well described and accounted for in
analysis
1 = withdrawals described and analysis not possible
0 = no mention, inadequate, or obvious differences
and no adjustments
C. Were the outcome assessors blind to treatment
status?
2 = effective action taken to blind assessors
1 = small or moderate chance of unblinding
assessors
0 = not mentioned or not possible
D. Were the participants blind to assignment status
after allocation?
2 = effective action taken to blind participants
1 = small or moderate chance of unblinding of
participants
0 = not possible, not mentioned (unless
double-blind), or possible but not done
E. Were important baseline characteristics reported and
comparable?
The principal confounders were considered to be
age and sex
2 = good comparability of groups, or confounding
adjusted for in analysis
1 = confounding small, mentioned but not adjusted
for
0 = large potential for confounding, or not discussed
F. Were care programs, other than the trial options,
identical?
2 = care programs clearly identical
1 = clear but trivial differences
0 = not mentioned or clear and important
differences in care programs
G.Were the inclusion and exclusion criteria clearly
defined?
2 = clearly defined
1 = inadequately defined
0 = not defined
H.Were the interventions clearly defined?
2 = clearly defined interventions are applied with a
standardised protocol
1 = clearly defined interventions are applied but the
application protocol is not standardised.
0 = intervention and/or application protocol are
poorly or not defined
I. Were the outcome measures used clearly defined?
A general grading was given for all outcome
measures used since the number and type varied
between trials.
2 = clearly defined
1 = inadequately defined
0 = not defined
Studies were also ranked by quality of allocation





SPSS software version 17.0 (SPSS Inc, Chicago USA)
was used to derive summary statistics. The standardised
mean difference (SMD; difference in mean effects be-
tween groups divided by the pooled standard deviation)
was calculated for studies with a control group or mul-
tiple interventions. If the difference in mean effects
between groups was not available, the SMD was calculated
from the post-intervention mean scores and correspond-
ing standard deviation. The authors of one study, Yelland
et al. [34], were directly contacted for visual analogue
score (VAS) pain data which was collected but not in-
cluded in their publication, as this was required to calcu-
late the SMD of this study. Point estimates of effect were
statistically significant when the 95 % confidence interval
(CI) did not cross 0 for the SMD. Results favoured pro-
lotherapy when the SMD was positive, and favoured the
alternate intervention/control when the SMD was nega-
tive. SMD values of 0.0–0.5 were defined as a small effect,
0.5–0.8 a medium effect, and more than 0.8 a large effect.
These were calculated for short-term (4 weeks, range 0–
12), intermediate-term (26 weeks, 13–26) and long-term
(52 weeks, ≥ 52) data. Pooled SMD data were also calcu-
lated where possible to determine the statistical hetero-
geneity and overall effect for short-, intermediate- and
long-term data. Results were found to be statistically sig-
nificant when P ≤ 0.05. Overall effects were determined
using a random effects model if heterogeneity existed
(P < 0.10), and a fixed effect model if the data were
homogenous.
Results
A total of 203 studies were identified through electronic
search. Following the review of titles and abstracts, 26
studies were extracted for full review and finally, 8 stud-
ies were considered appropriate for inclusion (Additional
file 1). The reasons for the exclusion of studies are avail-
able in Additional file 2. A flow diagram, as described by
Moher et al. [43], is presented in Fig. 1 and highlights
the study selection process. The included studies were
assigned to one of three categories, based on the follow-
ing comparisons: prolotherapy injection for Achilles ten-
dinopathy, prolotherapy injection for plantar fasciopathy,
and prolotherapy injection for Osgood-Schlatter Disease.
Five studies were included in the Achilles tendinopathy
section, two studies in the plantar fasciopathy section
and one study in the Osgood-Schlatter Disease section
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of the review. All studies that met the inclusion criteria
reported dextrose as the primary prolotherapy agent. See
Table 1 for characteristics of included studies.
Quality assessment of included studies
The methodological quality scores for the eight included
studies are shown in Table 2. The maximum possible
score per study is 18 and each study was also graded for
allocation concealment (A - concealed assignment, B -
possible disclosure/unclear, C - disclosure likely).
The methodological quality of the studies in this re-
view was generally poor. Allocation concealment (the
procedure for protecting the randomisation process so
that the treatment to be allocated is not known before
the participants enter into the study) was poorly con-
ducted in the majority of studies analysed in this review.
The trials by Topol et al. [37] and Kim et al. [35] were
two exceptions, however concealment was implied but
not defined in both studies. All studies scored poorly for
participant blinding, which is particularly difficult in in-
jection intervention trials, with Topol et al. [37] the only
study providing any reference of participant blinding.
Only Yelland et al. [34] reported an adequate method
of allocation concealment. In general, the selection of
outcome measures was clinically appropriate and the
duration of surveillance was adequate. The blinding
of assessors was attempted in only two trials, although it is
recognised that it may be difficult to blind an assessor
when there may be evidence of the procedure being under-
taken from post-injection signs. Many studies also failed to
conduct, or provide data for, intention to treat analysis.
Yelland et al. [34] and Topol et al. [37] were the only
studies with a ‘good’ overall quality assessment (see
Table 2), with Yelland et al. [34] the only study in which
adequate evidence of concealed allocation was provided,
stating the randomisation schedule was generated and
administered by telephone independently by the NHMRC
Clinical Trials Centre in Sydney, Australia. Topol et al.
[37] reported use of a random numbers table for assign-
ment to each intervention group and stated that this was
blinded to the participants, guardian and treating/evaluat-
ing physician; however, again, no specific mention was
made of how this allocation was concealed. Kim et al. [35]
used alternation of participants as a method of randomisa-
tion but did not define the method of concealment.
All other studies used a prospective single intervention
case-series methodology, thus no randomisation or allo-
cation concealment was carried out, with resulting ‘poor’
Fig. 1 Quorum flowchart of the reviewing process
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Table 1 Characteristics of included studies




Intervention/s Outcome measures Exclusion criteria





pilot study of an old
treatment.
To assess the clinical
effectiveness of prolotherapy












Intervention: Pain results were monitored
with individual prolotherapy
recovergrams which were
compiled in a study
recovergram. A satisfaction






20 %/lignocaine 0.1 %;
















Intervention: Follow up was conducted
by an independent party
with a standard
questionnaire assessing
















treat chronic tendinosis of
the Achilles tendon: a pilot
study.
Reporting on treatment of










Location: Canada. Intervention: Improvement in VAS1, VAS2
and VAS3; satisfaction rating,
as well as sonographic
measurements of tendon





with acute trauma, surgery
or interventional




≤2 mL prolotherapy, dextrose
25 %/lignocaine 1 %; every
6 weeks until either the












To report on changes in the
short-term sonographic
appearance at two year
follow-up for pain outcomes
in a large population with






Location: Canada. Intervention: Improvement in VAS1, VAS2
and VAS3; as well as
sonographic measurements






≤2 mL prolotherapy, dextrose
25 %/lignocaine 1 %; every
6 weeks until either the










To compare the effectiveness
of eccentric loading exercises
(ELE); based on Alfredson
protocol, with prolotherapy
used alone and in






Location: Australia. Intervention: Improvement in VISA-A,
pain stiffness and limitation
of activity scores, satisfaction
rating and treatment costs.
Previous steroid or
prolotherapy or surgery to
affected tendon, previous
completion of >50 % of
the Achilles ELE protocol,
and allergies or medical




≤5 mL dextrose 20 %/
lignocaine 0.1 %/ ropivacaine
0.1 % for 4–12 treatments
(n = 15); vs Comparator a):
Combination of prolotherapy
plus ELE (n = 14); vs
















Table 1 Characteristics of included studies (Continued)









To determine the efficacy









Location: Korea. Intervention: Pain, disability and
activity limitation
subscales, measured
by means of the FFI.
Local steroid injections
within 6 months or
nonsteroidal anti-
inflammatory drugs
within 1 week prior to
randomisation, active




2 mL dextrose 15 %/
lignocaine 1.25 % (n= 11); vs
Comparator: 2 mL of
autologous PRP (n= 10).
Two injections into the
plantar fascia at interval of
2 weeks.
Mean age: 37.0.
Ryan [36] Sonographically guided
intratendinous injections
of hyperosmplar dextrose/
lignocaine: a pilot study for
the treatment of chronic
plantar fasciitis.




dextrose at reducing the pain
associated with chronic PF.
Prospective
case series.
Location: Canada. Intervention: VAS1, VAS2 and VAS3,
foot function index (FFI)
were recorded at baseline
and at final treatment
consultation (post-test).








≤2 mL dextrose 25 %/
lignocaine 1 %; injected
sonographic guidance;
6-week intervals.Mean age: 51.2.
Prolotherapy injection for Osgood-Schlatter Disease





versus supervised usual care











Intervention: The Nirschl pain phase









≥2 mL dextrose 12.5 %/
lignocaine 1 % solution
(n = 21); vs Comparator a):
≥2 mL lignocaine 1 %
solution (n = 22); vs
Comparator b): Supervised
standard therapy (n = 22).
Mean age: 13.3.
AT Achilles tendinopathy, VAS visual analogue scale, VAS1 pain during rest, VAS2 pain during normal daily activity, VAS3 pain during or after sporting activity, ELE eccentric loading exercises, VISA-A Victorian institute of















to ‘moderate’ quality assessment overall scores. Although
all studies had reasonable scores regarding the definition
and usefulness of outcome measurements (item I), they
were generally very poor in quality regarding intention
to treat analysis (item B) and blinding procedures (items
C, D), although this may not have been possible in sev-
eral of the studies.
Study characteristics
There were three randomised controlled trials and five
prospective case-series studies identified, the characte-
ristics of which are presented in Table 1. Lyftogt [30]
conducted a prospective case-series of 16 participants
with non-insertional Achilles tendinopathy, to evaluate
the clinical effectiveness of prolotherapy for relieving
painful symptoms. Subcutaneous prolotherapy injections
of 1 mL were performed weekly where possible with
final follow-up at 3 months post-final treatment. Lyftogt
[31] carried out a significantly larger study with similar
methods 2 years later and used three different prolother-
apy regimens: (i) dextrose 20 %/lignocaine 0.1 %, (ii) dex-
trose 30 %/lignocaine 0.1 %/ropivacaine 0.1 % and (iii)
dextrose 40 %/ropivacaine 0.1 % for 87, 31 and 26 partici-
pants respectively. In this study, Lyftogt’s [31] final follow-
up was undertaken independently after a mean period of
20 months. Both of Lyftogt’s studies involved mainly male
participants and treated only midportion Achilles tendino-
pathy [30, 31].
Maxwell et al. [32] conducted a prospective case-series
assessing pain, satisfaction and sonographic changes
following sonographically-guided hyperosmolar dextrose
injections in 36 participants (25 men and 11 women)
with chronic Achilles tendinopathy. VAS pain during
rest, VAS pain during normal daily activity and VAS pain
during or after sporting activity scores and sonographic
assessments were recorded 6 weeks after final treatment.
In addition, a telephone interview with each study par-
ticipant was performed a mean of 12 months (range
4.5–28 months) after the last treatment to assess the
medium- to long-term efficacy of dextrose injection ther-
apy. Ryan et al. [33] built on evidence presented in the
study by Maxwell et al. [32] in a prospective case-series
published 3 years later. Ninety-nine participants (58 men
and 48 women) with painful midportion (86) and inser-
tional (22) Achilles tendinopathy pain received the same
prolotherapy regimen, outcome measures and treatment
schedule as described by Maxwell et al. [32], however im-
provements were made on the length of follow-up with a
mean final follow-up time of 28.6 months.
Yelland et al. [34] compared weekly prolotherapy in-
jections with eccentric loading exercises and a combin-
ation of eccentric loading exercises plus prolotherapy
injections in 43 participants with painful Achilles tendi-
nopathy. The participants were randomly allocated using
a computer-generated randomisation schedule to receive
prolotherapy injections alone (15 participants), eccentric
loading exercisesalone (14 participants) or a combination
therapy of prolotherapy and eccentric loading exercises
(14 participants). Between 0.5 and 1 mL of solution was
injected at each tender point, most commonly the antero-
lateral and anteromedial margins of the tendon and on
the most posterior aspect of the tendon 2–7 cm from the
calcaneal attachment, as illustrated in Fig. 2. A maximum
total of 5 mL of solution was used, with the number of
treatments determined by the time it took to reach a pain-
free activity or until the participant requested to cease
treatment. Outcome assessments of VISA-A, VAS pain,
stiffness and limitation of activity scores, satisfaction rat-
ing and treatment costs were made at 6 weeks, 3, 6 and
12 months from initial treatment.
Kim et al. [35] compared the efficacy of autologous
platelet-rich plasma with prolotherapy injections in 21
participants with chronic recalcitrant plantar fasciopathy
aged from 19 to 57 years. Participants with odd participant
sequence numbers were allocated to the prolotherapy
group (11 participants), while participants with even
sequence numbers were placed in the autologous
platelet-rich plasmagroup (10 participants). The injection
Table 2 Quality of assessment for included trials
Study Pathology A B C D E F G H I Total/18 Quality assessment Allocation concealment
Kim et al. [35] PF 1 1 0 0 2 2 2 2 2 12 Moderate B
Lyftogt [30] AT 0 0 0 0 0 0 1 2 2 5 Poor C
Lyftogt [31] AT 0 0 0 0 0 0 1 1 2 4 Poor C
Maxwell et al. [32] AT 0 1 0 0 0 2 2 2 2 9 Moderate C
Ryan et al. [36] PF 0 2 0 0 0 2 2 1 2 9 Moderate C
Ryan et al. [33] AT 0 1 0 0 0 2 1 1 2 7 Moderate C
Topol et al. [37] OSD 1 2 1 1 1 2 2 2 2 14 Good B
Yelland et al. [34] AT 2 2 2 0 0 2 2 2 2 14 Good A
PF Plantar fasciopathy, AT Achilles tendinopathy, OSD Osgood-Schlatter disease, A concealed assignment, B withdrawals described, intention to treat analysis,
C assessors blinded, D participant blinded, E groups comparable at entry, F identical care programs, G inclusions/exclusions defined, H interventions defined,
I outcomes defined
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procedure was performed under aseptic conditions using
a 22-gauge needle. Figure 3 illustrates the location of
needle insertion through the medial heel, which was per-
formed under ultrasound-guidance toward the target area.
Approximately 2 mL of platelet-rich plasmaor prolother-
apy solution was injected using a peppering technique,
which involved a single skin portal followed by five pene-
trations of the fascia. Both interventions consisted of two
injections at 2-weekly intervals. Final follow-up occurred
between 10 and 28 weeks from initial treatment date, with
all participants completing the follow-up with the excep-
tion of one in the platelet-rich plasmagroup. Ryan et al.
[36] conducted a prospective case-series to evaluate the
effectiveness of sonographically-guided prolotherapy in-
jections in reducing pain in 20 participants (17 women)
with chronic plantar fasciopathy. Outcome measures in-
cluding the Foot Function Index (FFI) and VAS pain were
recorded at baseline and the final treatment consultation,
with a follow-up telephone interview conducted a mean of
11.8 months (range 6–20 months) following the partici-
pant’s final session.
In the only study included in this analysis that assessed
prolotherapy injections for Osgood-Schlatter Disease,
Topol et al. [37] performed a double-blinded randomised
controlled trial involving 65 knees in 54 participants. Par-
ticipants (mean age 13.3 years) were randomly allocated
to receive prolotherapy injections (21 knees), lignocaine
injections (22 knees) or supervised usual care (22 knees).
Locations and technique for the lignocaine and prolother-
apy injections can be seen in Fig. 4. Topol et al. [37] used
the Nirschl Pain Phase Scale (NPPS), which is a 7-level
measure of sports inhibition and sports-related symptoms.
The threshold goals in the study were a NPPS score <4,
where symptoms may be present however sport is unin-
hibited, or a NPPS score below 4 where asymptomatic
sport occurs. This study assessed sport alteration and
sport-related symptoms in adolescent athletes with
Osgood-Schlatter Disease. All participants that still
reported sports-related symptoms after 3 months, the
point at which the actual injectant was revealed to
the treating physician and participant, could then
Fig. 3 Plantar photograph of left foot illustrating the injection site
used by Kim et al. [35] for management of plantar faciopathy. The ‘X’
marking represents the medial heel site used for the ultrasound-guided
platelet-rich-plasma and prolotherapy injections, with the orange lines
demarking the medial band of the plantar fascia
Fig. 4 Anteroposterior photograph of knee illustrating injection
points marked ‘X’ starting over the most distal area of pain on the
tibial tuberosity and moving proximally in 1-cm increments to the
most proximal painful point with pressure as described by Topol
et al. [37]. The orange lines represent the attachment of the patellar
tendon from the patella to the tuberosity or its fragments
Fig. 2 Posterior photograph of right lower leg showing injection
points most commonly used by Yelland et al. [34] for management
of Achilles tendinopathy. The ‘X’ markings represent the anteromedial,
posterior midline and anterolateral margins of the tendon, with orange
lines demarking the Achilles tendon
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choose to receive prolotherapy injections. This was
offered monthly until 12 months after either elimination
of symptoms or plateau of improvement. Athletes were
not required to receive dextrose injection if they were
satisfied with their status at 3 months.
Effects of interventions
Pooled standardised mean differences for short-,
intermediate- and long-term data
Meta-analysis was only possible for three of the included
studies. SMDs were calculated for Yelland et al. [34],
Kim et al. [35] and Topol et al. [37] and are presented in
the forest plots in Fig. 5. Substantial heterogeneity was
present in the comparison between prolotherapy and
other interventions for short- (P < 0.001, I2 = 79 %),
intermediate- (P = 0.029, I2 = 72 %) and long-term data
(P = 0.001, I2 = 81 %). A statistically significant total effect
was found between prolotherapy and other intervention
for long-term data (P = 0.024), with the total (random ef-
fects) SMD found to be 0.48 (0.15 to 2.03). Short-term
data approached statistical significance (P = 0.052) with a
total SMD of 0.38 (−0.01 to 1.48) while the intermediate-
term total SMD of 0.47 (−0.55 to 1.33) was not found to be
statistically significant (P = 0.410). Data from the remaining
five studies could not be pooled due lack of a comparator
group, and qualitative and quantitative analysis of all indi-
vidual studies are discussed in the following pathology-
specific sections.
Prolotherapy injections for treatment of Achilles tendinopathy
Five studies of moderate to good methodological quality
involving 338 participants reported on management of
painful Achilles tendinopathy with prolotherapy injec-
tions. The studies included: prolotherapy as the only
intervention with no control group (Lyftogt [30], Lyftogt
[31], Maxwell et al. [32], Ryan et al. [33]); and prolother-
apy versus eccentric loading exercises versus combination
of prolotherapy plus eccentric loading exercises (Yelland
et al. [34]).
Pain All five studies reported a significant reduction in
pain following prolotherapy treatment. Lyftogt [30] re-
ported a mean reduction in VAS pain score of 62.0 mm
by final 16-week follow-up. In another study, Lyftogt
[31] reported a mean reduction in VAS scores for three
different prolotherapy regimens with results as follows:
60.2 mm for dextrose 20 %/lignocaine 0.1 %, 56.0 mm
for dextrose 30 %/lignocaine 0.1 %/ropivacaine 0.1 %
and 56.0 mm for dextrose 40 %/ropivacaine 0.1 % with
a mean length of treatment 8.0, 7.6 and 8.7 weeks
Fig. 5 Standardised mean differences (SMD) for improved pain after prolotherapy vs comparator intervention for plantar fasciopathy, Osgood
Schlatter disease and Achilles tendinopathy
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respectively. Not enough data was supplied to calcu-
late the 95 % CIs for these studies. Maxwell et al.
[32] reported a mean percentage reduction at final
follow-up for VAS1 (pain during rest) of 88.2 % (p <
0.001), for VAS2 (pain during normal daily activity)
of 84.0 % (p < 0.001), and for VAS3 (pain during or
after sporting activity) of 78.1 % (p < 0.001) following
sonographically-guided intratendinous prolotherapy injec-
tions. The same injection regimen was repeated 3 years
later in a study by Ryan et al. [33] who reported significant
improvement in pain scores for both midportion Achilles
tendinopathy [VAS1 90.3 % (p < 0.001), VAS2 81.07 (p <
0.001), VAS3 76.3 % (p < 0.001)] and insertional Achilles
tendinopathy [VAS1 91.5 % (p < 0.001), VAS2 80.5 %
(p < 0.001), VAS3 74.6 % (p < 0.001)] participants from
baseline to final follow-up.
Yelland et al. [34] were contacted for unpublished
VAS pain data used in the study from which the SMD
between intervention groups was calculated. As can be
seen in the forest plot in Fig. 5, a large effect was seen in
favour of prolotherapy vs eccentric loading exercises for
short- (SMD 0.82, 95 % CI −2.18 to 2.25), intermediate-
(1.26, 95 % CI −0.77 to 1.54) and long-term pain (0.84,
95 % CI −1.54 to 3.23). For prolotherapy compared to
combination (prolotherapy plus eccentric loading exer-
cises) therapy, a small and moderate effect was found in
favour of prolotherapy for short- (0.04, −2.18 to 2.25)
and intermediate-term (0.56, 95 % CI −1.60 to 2.72)
pain, however a small effect in favour of combination
therapy was seen long-term (−0.04, 95 % CI −2.04 to
1.97). It should be noted that although the SMDs for
VAS pain favoured prolotherapy and combination therapy
over eccentric loading exercises, none of these differences
were found to be statistically significant. Similarly, Yelland
et al. [34] reported decreases in pain scores from baseline
for eccentric loading exercises, which was significantly less
than for prolotherapy at 6 months and for combined treat-
ment at 12 months. However, more importantly, the
difference between treatment groups over time was not
significant overall.
Pathology or location-specific outcome measures At
12 months, Yelland et al. [34] reported that the propor-
tions achieving the minimum clinically important change
for VISA-A were 73 % for eccentric loading exercises,
79 % for prolotherapy and 86 % for combined treatment.
Mean improvements in VISA-A scores at 12 months were
23.7 points for eccentric loading exercises, 27.5 points for
prolotherapy and 41.1 points for combined treatment. At
6 weeks and 12 months, these increases were significantly
less for eccentric loading exercises than for combined
treatment. Compared with eccentric loading exercises,
reductions in stiffness and limitation of activity occurred
earlier with combined treatment.
Satisfaction Lyftogt [30] reported 88 % satisfaction for
the single cohort at 16-week follow-up, while the satis-
faction for each treatment group in Lyftogt [31] was: A)
96 % at mean 21-month follow-up, B) 88 % at mean
12-month follow-up, and C) no data supplied. Twenty
of 32 participants were asymptomatic at 12 months
after treatment in the study by Maxwell et al. [32],
with 19 participants giving a satisfaction level of 95–100 %.
Only one participant had moderate symptoms and de-
scribed only 50 % satisfaction level. Yelland et al. [34]
found the percentage of participants reporting “satisfac-
tion” or “extreme satisfaction” with treatment at 12 months
was 50 % for eccentric loading exercises, 69 % for pro-
lotherapy and 71 % for combined treatment, however the
differences between groups was not statistically significant.
Sonographic measurements of tendon thickness, size
of hypoechoic region and intratendinous tear size
Maxwell et al. [32] reported the mean Achilles tendon
thickness decreased from 11.7 to 11.1 mm (p < 0.007)
following prolotherapy treatment. The number of ten-
dons with anechoic clefts or foci was reduced by 78 %.
Echogenicity improved in 6 tendons (18 %), but was
unchanged in 27 tendons (82 %). Neovascularity was
unchanged in 11 tendons (33 %) but decreased in 18
tendons (55 %); no neovascularity was present before or
after treatment in the remaining tendons. Similarly, Ryan
et al. [33] also noted a reduction in painful symptoms
corresponded with improvements in some aspects of the
sonographic appearance of the Achilles tendon. There
were no differences in the recorded thicknesses of the
Achilles tendon at either injury site. There was a greater
reduction in the number of participants with both grade
3 or 2 hypoechogenicity and neovascularization in the
midportion group at post-test compared with the inser-
tional group.
Adverse events Lyftogt [30], Lyftogt [31] and Ryan et al.
[33] did not provide information on post-intervention
complications. Maxwell et al. [32] reported no adverse
effects or complications following prolotherapy injec-
tions, and concluded hyperosmolar dextrose has “an ex-
cellent safety profile”. Yelland et al. [34] was the only
study to report an adverse effect; in which one partici-
pant in the eccentric loading exercises group had a par-
tial calf tear while playing tennis. An independent sports
physician did not attribute this to the eccentric loading
exercises program.
Prolotherapy injections for treatment of plantar fasciopathy
Two studies of moderate to good methodological quality
involving 41 participants reported on management of
painful plantar fasciopathy with prolotherapy injections.
The studies included: prolotherapy versus platelet-rich
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plasma (Kim et al. [35]); and prolotherapy as the only
intervention with no control group (Ryan et al. [36]).
Pain Both Kim et al. [35] and Ryan et al. [36] reported a
significant reduction in painful symptoms following pro-
lotherapy injections in participants with painful plantar
fasciopathy. Figure 5 shows the SMD for improvement
in pain after prolotherapy vs platelet-rich plasma injec-
tions, with Kim et al. [35] reporting a small short-term
(SMD −0.26, 95 % CI −1.88 to 1.37) and moderate
intermediate-term (−0.52, 95 % CI −2.56 to 1.52) effect
in favour of platelet-rich plasma. However, both pro-
lotherapy and platelet-rich plasma interventions had sig-
nificant improvements on pain levels, with a 17.1 % and
29.7 % improvement at 28 weeks respectively. Ryan et al.
[36] found a significant decrease (p < 0.001) in all mean
VAS items from pre-test to post-test: VAS1 (36.8 to
10.3), VAS2 (74.7 to 25.0) and VAS3 (91.6 to 38.7) with
no significant changes at the final follow-up interview.
Pathology or location-specific outcome measures
Kim et al. [35] found the mean Foot Function Index
total and subcategory score improvements were greater
in the platelet-rich plasma group (30.4 %) compared with
the prolotherapy group (15.1 %), however no statistically
significant differences were noted at any follow up. In the
pain and disability subcategories, both groups showed sig-
nificant improvements at the last re-evaluation.
Adverse events Ryan et al. [36] reported no complica-
tions from prolotherapy injections into the plantar
fascia. Kim et al. [35] found most participants in both
intervention groups reported local pain or discomfort
that started on the day of injection and subsided grad-
ually, however no other complications of either injection
therapy were reported.
Prolotherapy injections for treatment of Osgood-Schlatter
disease
One trial of moderate to good methodological quality
involving 54 participants reported on management of
painful Osgood-Schlatter disease with prolotherapy in-
jections. The study included prolotherapy versus usual
care versus lignocaine injections (Topol et al. [37]).
Pain SMD calculations of the results reported by Topol
et al. [37] found a large effect size in favour of prolotherapy
versus usual care or lignocaine injections for short-term
(prolotherapy versus usual care SMD 2.39, 95 % CI 1.69 to
3.08; prolotherapy versus lignocaine 1.16, 95 % CI 0.85 to
1.48) and long-term pain levels (prolotherapy versus usual
care 2.43, 95 % CI 1.67 to 3.18; prolotherapy versus lig-
nocaine 1.33, 95 % CI 0.57 to 2.09) – illustrated in Fig. 5.
Figure 5 also shows that the prolotherapy intervention had
a large positive effect when compared to usual care and lig-
nocaine, with the lower confidence interval not crossing
zero (the line of no effect) for both short- and long-term
outcomes.
Return to activity Topol et al. [37] reported unaltered
sport was more common in both prolotherapy-treated
(21 of 21 versus 13 of 22; p = 0.001) and lignocaine-treated
(20 of 22 versus 13 of 22; p = 0.034) knees when compared
with usual care at 3 months In addition, asymptomatic
sport was more frequent in the prolotherapy-treated knee
group than either lignocaine-treated (14 of 21 versus 5 of
22; p = 0.006) or usual care-treated (14 of 21 versus 3 of
22; p < 0.001) knee groups. At 1 year, asymptomatic sport
was more common in the prolotherapy-treated knee
group than in groups that had knees treated with only lig-
nocaine (32 of 38 versus 6 of 13; p = 0.024) or only usual
care (32 of 38 versus 2 of 14; p < 0.001).
Adverse events Topol et al. [37] did not provide informa-
tion on post-intervention complications for any of the par-
ticipant groups, however the study reported 100 % of the
prolotherapy intervention group participants achieved un-
altered sport by the final blinded period follow-up without
missing a monthly injection, indicating no complications
occurred following prolotherapy injections in the trial.
Discussion
Data was only able to be pooled and analysed for the
three studies with multiple interventions, and while a
statistically significant overall difference between pro-
lotherapy and other interventions was found for short-
and long-term SMD data, the small sample size and test-
ing of various pathologies reduces the weight of these
findings. Considerable variance between the studies
was determined for short-, medium- and long-term data
(I2 = 72–81 %), a consequence of both clinical and meth-
odological diversity among the studies. The assessment of
outcome was hampered by the variety and quality of the
outcomes recorded in the eight studies that were included.
The VAS for assessment of pain was the most frequently
used outcome, either generally or specific to rest and
activity (VAS1; VAS2; VAS3). Pain was also measured
through the VISA-A and NPPS measures, further compli-
cating comparisons between studies. Ryan et al. [33] suc-
cessfully built on the previous research of Maxwell et al.
[32] by using the same pain VAS scores and sonographic
Achilles tendon measurements, however these were the
only repeated outcome measurements analysed in this
review.
All five studies included in this review (Lyftogt [30];
Lyftogt [31]; Maxwell et al. [32]; Ryan et al. [33]; Yelland
et al. [34]) showed moderate evidence of improved Achilles
tendinopathy pain, function and participant satisfaction
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with corresponding sonographic measurements following
prolotherapy intervention. Yelland et al. [34] was the only
study to compare prolotherapy injections with the Achilles
tendinopathy reference standard treatment of eccentric
loading exercises and reported superior pain and stiffness
reduction at 6-months, with the benefit of minimal effort
required of the participant, and the technique being a
time-efficient approach. Yelland et al. [34] also found
combination therapy of eccentric loading exercises plus
prolotherapy was the most beneficial intervention for im-
provement in VISA-A and VAS pain scores at 12-months.
No adverse events following prolotherapy for manage-
ment of Achilles tendinopathy were reported in any of the
studies included in our analysis. Despite the positive over-
all results presented in these studies the heterogeneity in
treatment approaches and control groups as well as poor
overall methodology prohibited an extensive meta-analysis
and significantly limits the strength of conclusions for this
review.
The two studies relating to chronic plantar fasciopathy
included in this review indicate that injections of dex-
trose and lignocaine reduces pain in the majority of
participants. Eighty percent of participants undergoing
ultrasound-guided treatment in the study by Ryan et al.
[36] reported good to excellent outcomes in pain reduc-
tion at the cessation of their treatment. The case-series
design and the lack of control group in this study limit
the evidence of the treatment effect, however the results
are promising for patients experiencing chronic plantar
fasciopathy unresponsive to conservative treatment. Kim
et al. [35] compared prolotherapy with platelet-rich
plasma; an increasingly popular treatment that, like pro-
lotherapy, is hypothesised to stimulate processes associ-
ated with healing. The results of Kim et al. [35] indicate
that there is no clear advantage or disadvantage in using
either prolotherapy or platelet-rich plasma for manage-
ment of chronic plantar fasciopathy, with improvements
in both pain and function seen in both intervention
techniques. Platelet-rich plasma injections did result in
better outcomes in FFI total scores and the pain sub-
category, although no significant difference was noted
between groups and both treatments markedly reduced
pain within a few months after injection indicating that
both may be an effective treatment option for chronic
plantar fasciopathy. However, these findings need to be
considered in the context that a true control group (i.e.
placebo) was not included, so it is not known how ef-
fective they are relative to no treatment. Ryan et al. [36]
and Kim et al. [35] both reported no adverse events fol-
lowing prolotherapy or platelet-rich plasma injections.
The single trial that assessed prolotherapy for treat-
ment of Osgood-Schlatter disease included in this review
found that prolotherapy was superior to usual care
for improving unaltered sport and asymptomatic sport
outcomes. Topol et al. [37] reported lignocaine injec-
tions resulted in similar improvement to prolotherapy
in unaltered sport; with 90 and 100 % of participants
reporting unaltered sport at 3-months for lignocaine
and prolotherapy-treated groups, respectively. However
Topol et al. [37] found evidence that prolotherapy was sig-
nificantly superior to lignocaine injection for improvement
in asymptomatic sport, with 67 % of the prolotherapy
group and 23 % of lignocaine group reporting complete
asymptomatic sport at 3-months. The duration of surveil-
lance was a 3-month blinded period, which was sufficient
to see immediate improvements in outcome, but further
long-term follow up would have been more beneficial in
evaluating the effectiveness between groups. Adverse
events were not reported in this study.
This systematic review has several limitations. Firstly,
SMDs were only calculated for three studies; it was not
possible to pool SMDs in the five remaining studies as
no comparator group was present. Secondly, the review
was restricted to prospective studies, so only three path-
ologies were included; Achilles tendinopathy, plantar fas-
ciopathy and Osgood-Schlatter disease. This may have
excluded useful clinical information and by excluding
studies assessing prolotherapy for ligament disorders a
large body of data was not considered. However, the
pathomechanics and prolotherapy mechanism of action
differ greatly for ligament pathologies and their inclusion
may have reduced the specificity and generalisability of
our systematic review. Thirdly, the prolotherapy regi-
men, including concentration of dextrose, agent and
concentration of additional local anaesthetic/s, and the
frequency, volume and total number of injections varied
significantly between studies. Only a few of the variety
of prolotherapy interventions have been evaluated and
the interventions that have been evaluated assessed dif-
ferent anatomical and physiological pathologies, thus no
conclusive comparisons can be made between them.
Fourthly, the heterogeneity of study populations was also
generally poor, particularly regarding sex of participants,
with the majority of studies being heavily skewed to-
wards one sex type that created large potential for con-
founding. Finally, the greatest limitation of the study was
the lack of high quality randomised controlled trials
available in the literature; in our review, the conclusions
about prolotherapy injections in the lower limb were
made on the basis of only three randomised controlled
trials. To address these limitations, it is essential that
future studies should analyse prolotherapy for tendino-
pathy and fasciopathy using high-quality randomised
controlled trial methodology. Future research should also
consider inclusion of other musculoskeletal disorders,
recruitment of large sample sizes, standardisation of co-
interventions, long-term follow-up, and systematic report-
ing of adverse events are needed.
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Conclusions
This systematic review identified eight studies that re-
ported on the effectiveness of prolotherapy for treatment
of lower-limb tendinopathies and fasciopathies and
found that there is limited evidence to support pro-
lotherapy for the treatment of these pathologies. Of the
studies that were reviewed, only a small proportion were
randomised controlled trials, with the majority of studies
employing a prospective case-series design using a rela-
tively small sample size and no control or usual care
group. With these limitations in mind, analysis of the
three randomised controlled trials that were included in
this review suggests that prolotherapy injections may be
superior or at least comparable to eccentric loading
exercises for Achilles tendinopathy, platelet-rich plasma
for plantar fasciopathy, and usual care or lignocaine injec-
tions for Osgood-Schlatter disease. No study in this review
reported an adverse event following prolotherapy injec-
tion. Further research using large, methodologically-sound
randomised controlled trials is needed to support the
use of prolotherapy for lower-limb tendinopathies and
fasciopathies.
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